The Scientific Committee published the first Agenda of the 8th World Conference on Targeting Phage Therapy, which will be held on June 10-11, 2025, at DoubleTree by Hilton Berlin Kudamm, Berlin, Germany. Read More
Communications Accepted for Short Oral
DUOFAG – Human Clinical Trial Phase I
Dana Štveráková, MB PHARMA s.r.o.,Czech Republic
Successful Eradication of Chronic Pseudomonas Aeruginosa Infection with Personalised Bacteriophage Therapy in Children with Cystic Fibrosis: An Early Phase Clinical Trial
Jagdev Singh, The Children’s Hospital at Westmead, Australia
Endolysin (Lysk04) Combined with Plant-Derived Phenylpropanoid Disrupt Outer Membrane Barriers and Exhibits Broad-Spectrum Antibacterial Activity Against High-Risk Gram-Negative Pathogens
Susweta Das, Dayananda Sagar University, India
Biohybrid Composites of Platelet-Rich Fibrin and Gelatin Hydrogel Beads (Nano/Micro) for Targeted Phage Delivery in the Treatment of Infected Wounds
Farzaneh Moghtader, TiPhage, Turkey
Anti-Quorum Sensing Phages Rescue Galleria mellonella Larvae from Pseudomonas aeruginosa Infection
Kira Céline Koonce, University of Copenhagen, Denmark
First Use of Phage Therapy in Canada for the Treatment of a Life-Threatening, Multidrug-Resistant Staphylococcus Epidermidis Periprosthetic Joint Infection: An N-of-1 Trial
University of Ottawa at the Ottawa Hospital, Canada
Five years of adaptive phage therapy in the intensive care unit: Prospects, Limitations, Opportunities
Ekaterina A. Chernevskaya, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Russia
Freeze-Dried Tablets for Therapeutic Application of Bacteriophages
Marie Komárková, Masaryk University,Czech Republic
Novel Mycobacteriophages as a Promising Adjunct in the Fight Against Drug-Resistant TB and NTM Infections
Anthony Vocat, Lausanne University Hospital, Switzerland
Collateral Effects of Bacteriophage Resistance on Antibiotic Sensitivity in Pseudomonas Aeruginosa
Laura Rianne Baars, Leiden University, Netherland
Rapid and Specific Detection of Pathogenic Bacteria using Recombinant Receptor Binding Proteins of Bacteriophages
Peter Braun, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Germany
PHAGE–Postbiotic Synergy: a Novel Strategy against Pseudomonas Aeruginosa in Burn Wound Infection in Galleria Mellonella
Mine Egin, Karadeniz Technical University, Turkey
The Lausanne University Hospital GMP Production Pipeline for Manufacture of Therapeutic Bacteriophages
Gregory Resch, Lausanne University Hospital, Switzerland
A Multifaceted Experience with Phage Therapy: A Short Review of Successful and Challenging Cases across Multiple Body Systems
Mariam Dadiani, Eliava Phage Therapy Center, Georgia
Phage P04 Loaded Polysaccharide Hydrogel to Combat Biofilm-Forming Klebsiella Pneumoniae Infected Lesions
Harshitha N, Dayananda Sagar University, India
Coevolution of Bacteriophages Enhances Biocontrol of Shiga Toxin-Producing Escherichia Coli in Food Matrix
Nicola Mangieri, University of Milan, Italy
Phage-Antibiotic Composite Efficacy on Dual-Species Biofilm
Tea Glonti, Queen Astrid Military Hospital, Belgium
Broad-Spectrum Lytic Bacteriophages from Wastewater as Therapeutic Candidates against Antibiotic-Resistant Clinical Strains
Erva Rakici, Recep Tayyip Erdogan University, Turkey
Isolation, Characterization and Anti-Biofilm Activity of Lytic Bacteriophage K2 against Klebsiella Pneumoniae Isolates
Damla Damar Celik, Marmara University, Turkey
From Biology to Business: INCATE as a Catalyst in the Antibacterial Innovation Pipeline
Mercedes Gonzalez Moreno, Hans KnöllInstitute (HKI), Germany
Cure of a Difficult-To-Treat Pseudomonas Aeruginosa Canine Chronic Otitis Externa (Oe) with the PyoBacteriophage Cocktail Followed by Antibiotics
Raphaël Baudin, Lausanne University Hospital (CHUV), Switzerland
AWMF Sk2 Guideline Personalized Bacteriophage Therapy in Germany
Simone Lieberknecht-Jouy, University Hospital Frankfurt, Germany
New Insights into Bacteriophage Therapy in Dogs
Eva Maria Kalbhenn, LABOKLIN GmbH & Co. KG, Germany
Source-Dependent Variability in Staphylococcus Aureus Susceptibility to Bacteriophage Infection
Hanife Nur Karakoc Parlayan, KaradenizTechnical University Trabzon, Turkey
Phage Heteroresistance in Clinical Klebsiella Pneumoniae Isolates: Impact of Differential Capsule Expression on Phage Efficacy
Iris Najjar, Escola Paulista deMedicina-Universidade Federal de São Paulo, Brazil
From Cells to Larvae: Two-Front Approach to Salmonella Eradication Using Bacteriophage Vb_Sen-Miriam1
Łukasz Grabowski, University of Gdansk, Poland
In Ovo Phage Administration as a Novel Prophylactic Approach against Salmonella Typhimurium in Broiler Chickens
Jan Torres-Boncompte, Centro de CalidadAvícola y Alimentación Animal de la Comunidad Valenciana (CECAV), Spain
Companies, Hospitals, Clinical Centers, and Industry Organizations
Jafral (Supporter)
Amazon
Apothekendienstleistungen
Aptar Radolfzell GmbH
Centro de Calidad Avícola y Alimentación Animal de la Comunidad Valenciana
ArGe Teknoloji Sanayi ve Ticaret Anonim Şirketi
FagoFarma
TiPHAGE
Grachtenhaus-Apotheke e.K.
German Collection of Microorganisms and Cell Cultures GmbH
Inteliphage
Kanzlei BRENNER
Komplementäre Tiermedizin GmbH
LABOKLIN GmbH & Co. KG
Laboklin Phage Center
Laboratorios Syva
MB Pharma
MicrobiotiX
Medios AG
Nordmark Pharma
Otsuka Pharmaceutical CO.
Phileo by Lesaffre
Phagos
Precise Health SA
PrecisionPhage
Poulpharm
Qiagen
Rime Bioinformatics
Salem Microbes
Academic Hospital Bundeswehr Berlin
Center de investigación en red – Enfermedades Respiratorias
Centre hospitalier universitaire vaudois
IIS-Fundación Jiménez Díaz and CIBERINFEC-Consorcio Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Infecciosas
Federal research and clinical center of intensive care medicine and rehabilitology
Hannover Medical School
Shanghai Public Health Clinical Center
Victor Babes University of Medicine and Pharmacy Timisoara
Vivantes Klinik Bavaria Kreischa
Universities and Academic Institutions
Charles University
Charité – Universitätsmedizin Berlin
Comenius University in Bratislava
Delft University of Technology
Institute of Pharmacology and Toxicology, Veterinary Medicine
INSERM
Karadeniz Technical University
Kyorin University
Nanyang Technological University
Leibniz Institute DSMZ
Marmara University
Masaryk University
Max Planck Inst Molecular Genetics
Monash University
HMU Health & Medical University Erfurt
Rakuno Gakuen University
Recep Tayyip Erdoğan University
Stockholm University
Tel Aviv University
UCLouvain
Università degli Studi di Milano
University of Bologna
University of California, San Diego
Université de Paris
University of Copenhagen
University of Helsinki
University of Milan
University of Pisa
University of Roma Tor Vergata
University of Southampton
University of Warwick
Vrije Universiteit Brussel
Yale University
This session provides a comprehensive and hands-on approach to the entire phage product lifecycle, from laboratory preparation to industrial-scale production and market entry. Experts will address both practical challenges and administrative requirements, ensuring that participants leave with actionable insights.
Key topics include: Technical & Manufacturing Aspects, Regulatory & Administrative Aspects, Business & Market Strategy.
The 7th World Conference on Targeting Phage Therapy 2024 on June 20-21 at Corinthia Palace in Malta was a great success. Over 40 presentations on the latest phage research were delivered to an audience of over 100 attendees representing 35 countries. Read more.